Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.46 |
| ▸ | DRD3 | P35462 | 8/20 | 0.46 |
| ▸ | HTR2A | P28223 | 7/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7244242 | 1.00 | DRD2 (0.46) | DRD2DRD3HTR2AUSP30HDAC3 | |
| SCHEMBL6816571 | 0.91 | DRD2 (0.48) | DRD2DRD3HTR2AUSP30HDAC3 | |
| SCHEMBL6823150 | 0.91 | DRD2 (0.48) | DRD2DRD3HTR2AUSP30HDAC3 | |
| SCHEMBL6816380 | 0.87 | DRD2 (0.50) | DRD2DRD3HTR2AUSP30KCNH2 | |
| SCHEMBL6816368 | 0.87 | DRD2 (0.50) | DRD2DRD3HTR2AUSP30KCNH2 | |
| SCHEMBL7246466 | 0.87 | DRD2 (0.50) | DRD2DRD3HTR2AUSP30KCNH2 | |
| SCHEMBL7239754 | 0.86 | USP30 (0.49) | DRD2DRD3HTR2AUSP30HDAC3 | |
| SCHEMBL7239758 | 0.86 | USP30 (0.49) | DRD2DRD3HTR2AUSP30HDAC3 | |
| SCHEMBL29358671 | 0.86 | USP30 (0.49) | DRD2DRD3HTR2AUSP30HDAC3 | |
| SCHEMBL5106853 | 0.86 | USP30 (0.49) | DRD2DRD3HTR2AUSP30HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000048-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-27 | — | — | EP | claimed |
| US-20010051623-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | US | claimed |
| US-20010051626-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxy-tryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | US | claimed |
| US-6313118-B1 | HYDROXYTRYPTAMINE RECEPTOR ANTAGONISTS | ASTRA AKTIEBOLAG (SE) | 2001-11-06 | — | — | US | claimed |
| EP-1000048-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | Astra Aktiebolag (SE) | 2000-05-17 | — | — | EP | claimed |
| WO-1999005134-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1999-02-04 | — | — | WO | claimed |
| US-6534652-B2 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | ASTRAZENECA AB (SE) | 2003-03-18 | — | — | US | disclosed |
| EP-1000048-B1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| US-6410532-B2 | 8-(PIPERIDIN-4-YL- OR PIPERAZIN-1-YL)-2-SUBSTITUTED-TETRALIN DERIVATIVES; SELECTIVE EFFECT AT A SUBGROUP OF 5-HYDROXY-TRYPTAMINE RECEPTORS, H5-HT1B RECEPTORS (PREVIOUSLY 5-HT1D BETA); ANTAGONISTS; MOOD DISORDERS, ANTIANXIOLYTIC | ASTRAZENECA AB (SE) | 2002-06-25 | — | — | US | disclosed |
| US-20010051623-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | US | disclosed |
| US-20010051626-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxy-tryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | US | disclosed |
| US-6313118-B1 | HYDROXYTRYPTAMINE RECEPTOR ANTAGONISTS | ASTRA AKTIEBOLAG (SE) | 2001-11-06 | — | — | US | disclosed |
| EP-1000048-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | Astra Aktiebolag (SE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005134-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051623-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | HTR1D, HTR1F, HTR2C | DRD2 49/4885DRD3 75/4885HTR2A 13/4885 |
| US-20010051626-A1 | 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxy-tryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic | HTR1D, HTR1F, HTR2C | DRD2 52/4885DRD3 65/4885HTR2A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.